Royalty Report: Cancer, Diagnostic, Medical – Collection: 363938


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Cancer
  • Diagnostic
  • Medical
  • Drugs
  • Antibody
  • Disease
  • Test/Monitoring
  • Pharmaceuticals
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 363938

License Grant
The parties agreed to terminate all prior agreements and replace with a worldwide royalty bearing license agreement for Nodify XL2 test for 15 years from the first commercial sale, ending in 2034.
License Property
Nodify XL2 is a blood-based lung cancer test to assess the risk of lung cancer to help identify the most appropriate treatment pathway.
Field of Use
Field of use is for the testing related to lung cancer.

IPSCIO Record ID: 27476

License Grant
The Licensor granted the Licensee, a long-time partner,  the exclusive rights to sell the products in China provided that the Licensee achieves local regulatory approvals within a 3-year period and does not export from China.
License Property
The Licensor is developing, testing and commercializing its non-invasive lung cancer risk test. The Electro Pulmonary Nodule Scan is a bioconductance measurement method to evaluate the risk of lung cancer in patients with lesions of the lung in well-controlled clinical trials.

The EPN Scan device is designed to provide further information on whether a lung legion may be cancerous after detection by CT Scan.

Field of Use
In February 2014, the Chinese licensee received approval to manufacture, but not market or sell, the device in China as a lung cancer risk stratification device.  On March 15, 2015 the licensee entered clinical trials at two prominent hospitals for the purpose of seeking approval to market and sell the EPN Scanner in China.

IPSCIO Record ID: 226676

License Grant
The Licensee retained exclusive rights to use certain processes and know-how for which Licensor has a patent pending.  The agreement also allows Licensor first right to acquire the Company’s lung cancer testing business at various intervals.
License Property
The patents relate to lung cancer testing.
Field of Use
The field of use is medical testing.

IPSCIO Record ID: 278110

License Grant
The Parties entered this agreement to develop and commercialize ficlatuzumab.  The non-opting out party shall have sole decision-making authority with respect to further development and commercialization of ficlatuzumab.

Licensor granted the perpetual, non-exclusive rights to certain intellectual property, including diagnostic data related to VeriStrat, with respect to the development and commercialization of ficlatuzumab.

License Property
Ficlatuzumab is a hepatocyte growth factor (HGF) inhibitory antibody.  Ficlatuzumab is currently being evaluated in squamous cell carcinoma of the head and neck (HNSCC) and metastatic pancreatic ductal cancer (PDAC).

VeriStrat® is Licensor’s proprietary companion diagnostic test.  VeriStrat test is a predictive and prognostic blood-based proteomic test for patients with advanced non-small cell lung cancer.

A retrospective exploratory analysis uses VeriStrat®, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO’s HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSA®) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC).

Field of Use
The field of use is the treatment of non-small cell lung cancer in poor prognosis patients.

IPSCIO Record ID: 65273

License Grant
The Licensor grants grants the Licensee an exclusive, royalty-bearing, non-transferable , sublicensable license under the Licensed Patents and Technical Information,  relating to molecular diagnostics for lung cancer, solely to make, have made, use, sell, offer for sale, and import the Licensed Products in the Licensed Field in the Territory during the Term.
License Property
62/163,766 Methods and Compositions for Diagnosing or Detecting Lung Cancers – Patent rights and technical information and know-how relating to molecular diagnostics for lung cancer, including, but not limited to confirmatory, companion and recurrence diagnostics for any type of lung cancer with detection through whole blood, fractionated blood, plasma, serum and/or other biological samples.
Field of Use
The Licensee  will obtain a license under such patent rights, technical information and know-how to develop and commercialize products for the non invasive cancer diagnostic testing including for lung cancer.

IPSCIO Record ID: 3603

License Grant
Licensee has resolved litigation concerning allegations relating to a 1998 licence agreement with licensor, an individual, for intellectual property involved in its cancer products. The company retains exclusive rights to the ColorectAlert, LungAlert and the breast cancer test technologies. Under the terms agreed, licensee has entered into an amendment of the existing licensing agreement relating to two existing US and Japanese patents for a technology that detects a carbohydrate marker associated with cancerous and precancerous conditions.
License Property
ColorectAlertâ„¢ is a novel test that identifies people at risk of colorectal cancer at the earliest stages of the disease. The test measures the amount of a cancer-associated carbohydrate, or sugar, in a sample of rectal mucus, which is taken by a physician during a routine digital rectal exam.  ColorectAlertâ„¢ requires a sample of rectal mucus to be taken by a doctor during a digital (gloved finger) rectal exam. This sample can be taken during a routine doctor visit. The sample is smeared onto a proprietary membrane and sent to a laboratory.  At the laboratory, the sample is treated with the enzyme galactose oxidase, then stained with Schiff’s reagent, which produces a color change. The treated sample is read with a color reader (spectrophotometer) to quantify the color change and determine the numeric ColorectAlertâ„¢ value.

LungAlert™ is a novel test that identifies patients at risk of lung cancer at the early stages of the disease. The test detects a cancer-associated sugar in a sample of sputum (phlegm), which is obtained in the doctor’s office by coughing into a cup. Currently, there is no screening test for lung cancer that has proven to save lives.

IPSCIO Record ID: 325366

License Grant
Through a partnership with a third party, Licensee develops and/or commercialize sugemalimab for worldwide sales which results in royalty payments to Licensor.
License Property
Sugemalimab (CS1001), an OmniAb-derived anti-PD-L1 monoclonal antibody used in combination with chemotherapy for lung cancer.
Field of Use
Field of use is for the first-line treatment of advanced squamous and non-squamous non-small cell lung cancer (“NSCLC”).

Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. The main subtypes of NSCLC Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

IPSCIO Record ID: 28356

License Grant
University grants to Licensee an exclusive worldwide license under Patent Rights to make, have made, use lease, offer to sell, sell and import the Licensed Products within the Licensed Field for the term of this Agreement.
License Property
The Telomerase Assay is a patent-pending blood test for lung cancer.

Valuable inventions, comprised of the Patent Rights identified in Exhibit A-1, and generally known as 'Telomerase Assay of Body Fluids for Cancer Screening and Assessment of Disease Stage and Prognosis''('Inventions') have been made by UM Personnel

Field of Use
'Licensed Field' The use of Patent Rights for cancer diagnostics in all fields.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.